Skip to main content
. 2024 Mar 28;24:361. doi: 10.1186/s12879-024-09246-8

Table 2.

Crude and adjusted analyses assessing the impact of PBD on postoperative HAIs

Variables Infection Non-infection Crude analysis Adjusted analysis
(n = 247) (n = 2595) RR, 95% CI P value aRR, 95% CI P value
PBD
 No 159(8.1) 1806(91.9) ref. ref.
 Yes 88(10.0) 789(90.0) 1.267(0.964,1.665) 0.09 1.112(0.828,1.493) 0.48
Type of PBD
 Non-PBD 159(8.1) 1806(91.9) ref. ref.
 PTBD 68(10.2) 599(89.8) 1.289(0.957,1.738) 0.095 1.144(0.830,1.576) 0.412
 EBS 11(8.0) 127(92.0) 0.984(0.520,1.860) 0.96 0.836(0.436,1.602) 0.588
 ENBD 9(12.5) 63(87.5) 1.623(0.792,3.324) 0.186 1.402(0.674,2.913) 0.366
Interval between PBD and PD
 Non-PBD 159(8.1) 1806(91.9) ref. ref.
 ≤1 week 20(12.0) 146(88.0) 1.556(0.949,2.552) 0.08 1.373(0.824,2.286) 0.224
 1–4 week 40(9.2) 395(90.8) 1.150(0.800,1.654) 0.45 0.985(0.672,1.443) 0.937
 ≥4 week 28(10.1) 248(89.9) 1.282(0.840,1.958) 0.249 1.162(0.748,1.806) 0.504

PBD preoperative biliary drainage, HAIs healthcare-associated infections, PTBD percutaneous transhepatic biliary drainage, EBS endoscopic biliary stenting, ENBD endoscopic nasobiliary drainage, RR risk ratios, RR risk ratios, aRR adjusted risk ratios, 95% CI 95% confidence interval